News
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...
The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...
The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.
A research team from the University of Oklahoma has pioneered a method that could accelerate drug discovery and reduce ...
In a precedential decision issued May 6, 2025, the Federal Circuit reversed in part and vacated in part a Delaware district ...
The FDA has communicated to Stealth BioTherapeutics that it would not meet elamipretide’s PDUFA target date for the treatment of Barth syndrome.
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
Novo Nordisk NOVO.B2.62%increase; green up pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results